Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesMedicure Inc

Medicure Inc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
4.0 CAD -0.12 ( 2.91%)
Last update at 2026-11-04T17:46:00Z
VOLUME
2110
Market Cap
14.09M

Momentum Score

…

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing MC-1 for the treatment of PNPO deficiency; and TARDOXAL for neurological indications, such as Tardive Dyskinesia. It offers products through retail and mail order pharmacies. The company was founded in 1997 and is headquartered in Winnipeg, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
4.00
Low
4.00
High
52 Week Price Range
0.83
Low
1.43
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public information on Medicure Inc (MPH.V) is limited; the company is listed on the TSX Venture and appears positioned in the specialty healthcare sector with a focus on developing and commercializing treatments for acute and critical care. Long-term growth may be driven by regulatory approvals, successful product commercialization and strategic partnerships, and investors may find potential upside from portfolio advancement in niche clinical areas.
Key risks include limited disclosure and market liquidity, reliance on external financing, and binary regulatory or commercial outcomes that could materially affect prospects.

Risk Score
Low

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
4.12
Dividend Yield
-
Revenue TTM
26.21M
Revenue Per Share
2.51
Gross Profit TTM
12.77M
Debt / Equity
0.03
ROE
-18.39%
Net Debt
-5.83M
ROCE
-12.86%
Diluted EPS TTM
-0.33

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -0.78M -0.90M 1.39M -0.76M -6.84M
Net income -1.04M -0.92M 1.36M -0.73M -6.84M
Selling general administrative 12.74M 4.13M 4.19M 2.70M 4.58M
Selling and marketing expenses - 8.31M 7.93M 10.31M 5.36M
Gross profit 13.09M 13.56M 16.07M 12.71M 5.13M
Reconciled depreciation 2.31M 2.17M 2.06M 3.15M 2.77M
Ebit - -0.85M 1.31M -0.57M -7.29M
Ebitda - 1.32M 3.37M 2.57M -4.51M
Depreciation and amortization - 2.17M 2.06M 3.15M 2.77M
Operating income -2.74M -0.85M 1.31M -0.57M -7.29M
Other operating expenses - 22.55M 21.87M 23.84M 19.72M
Interest expense 0.01M 0.02M 0.02M 0.04M 0.05M
Tax provision 0.26M 0.03M 0.02M -0.03M 0.25M
Interest income 0.21M 0.07M 0.01M 0.08M 0.04M
Net interest income 0.17M 0.07M -0.21M -0.35M 0.77M
Income tax expense - 0.03M 0.02M -0.03M 0.05M
Total revenue 21.91M 21.69M 23.07M 21.74M 11.61M
Total operating expenses 24.64M 14.41M 14.88M 14.80M 13.24M
Cost of revenue 8.82M 8.14M 6.99M 9.03M 6.48M
Total other income expense net 1.79M -0.04M 0.40M 1.68M 0.49M
Net income from continuing ops -1.04M -0.92M 1.36M -0.73M -6.84M
Net income applicable to common shares - - - -0.73M -6.84M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 29.68M 28.06M 29.90M 28.41M 34.05M
Intangible assets 9.35M 8.94M 10.62M 11.21M 13.60M
Other current assets - 1.14M - 0.00M 1.39M
Total liab 8.90M 8.16M 8.89M 10.00M 14.91M
Total stockholder equity 20.78M 19.90M 21.00M 18.41M 19.15M
Other current liab - 0.38M 0.18M 1.04M 5.00M
Common stock - 81.01M - 80.92M 80.92M
Capital stock 81.01M 81.01M 80.92M 80.92M 80.92M
Retained earnings -66.89M -65.85M -64.93M -66.30M -65.57M
Other liab - - - 0.70M 1.52M
Good will 3.38M 3.10M 3.18M 2.97M 2.99M
Other assets - - - 0.06M 0.16M
Cash 7.19M 6.37M 4.86M 3.69M 2.72M
Total current liabilities 8.39M 7.93M 8.39M 8.51M 12.31M
Current deferred revenue - 0.02M - - -
Net debt - -5.83M - - -
Short term debt - 0.32M - - -
Short long term debt total - 0.54M - - -
Other stockholder equity - 10.72M - -6.64M -6.50M
Property plant equipment - - - 1.61M 1.64M
Total current assets 15.90M 15.21M 14.85M 12.55M 15.68M
Net tangible assets - - - 4.22M 2.56M
Net receivables 5.26M 4.79M 5.53M 4.66M 5.25M
Inventory 3.28M 2.90M 3.22M 3.33M 5.14M
Accounts payable 7.93M 7.22M 7.13M 6.49M 6.39M
Accumulated other comprehensive income - -5.99M - - -
Non currrent assets other 0.10M 0.07M 0.06M 0.06M 0.16M
Non current assets total 13.78M 12.85M 15.05M 15.85M 18.38M
Capital lease obligations 0.87M 0.54M 0.85M 1.17M 1.45M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -0.74M -0.27M -0.31M -2.69M -7.24M
Change to liabilities - - 0.57M 0.02M -3.80M
Total cashflows from investing activities - - - -2.69M -7.24M
Net borrowings -0.37M - - -0.32M -0.24M
Total cash from financing activities -0.37M -0.30M -0.35M -0.32M -0.77M
Change to operating activities - - - 0.40M 0.70M
Net income -1.04M -0.92M 1.36M -0.73M -6.84M
Change in cash 0.82M 1.51M 1.16M 0.98M -10.25M
Begin period cash flow 6.37M 4.86M 3.69M 2.72M 12.96M
End period cash flow 7.19M 6.37M 4.86M 3.69M 2.72M
Total cash from operating activities 1.38M 2.08M 1.83M 3.99M -2.24M
Depreciation 2.31M 2.17M 2.06M 3.15M 2.77M
Other cashflows from investing activities - - - -1.88M -1.88M
Change to inventory -0.21M -0.03M 0.17M 0.47M 0.72M
Change to account receivables 0.15M 0.76M -0.86M 0.59M 5.08M
Sale purchase of stock - - 0.00M -0.37M -0.52M
Other cashflows from financing activities - 0.06M -0.31M -2.69M -7.24M
Change to netincome - - - 0.08M -0.87M
Capital expenditures 0.74M 0.27M 0.31M 0.82M 0.00M
Change in working capital -0.33M 0.47M -0.33M 1.49M 2.71M
Stock based compensation 0.20M 0.29M 0.05M 0.14M 0.32M
Other non cash items -0.17M 0.05M -1.33M -0.02M -1.09M
Free cash flow 0.64M 1.81M 1.52M 3.17M -2.24M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
MPH
Medicure Inc		 -0.12
2.91%		 4.00 - 13.48 0.54 0.81 0.42 7.84
RX
Biosyent Inc.		 0.30
1.78%		 17.15 19.10 15.85 3.96 4.11 3.31 11.03
DB
Decibel Cannabis Company Inc		 0.21
11.67%		 2.01 - 8.67 0.67 1.20 0.99 17.75
ZYUS
ZYUS Life Sciences Corporation		 0.03
9.38%		 0.35 - - 108.48 4.41 140.29 -4.26
LSL
LSL Pharma Group Inc.		 0.01
1.64%		 0.31 20.75 - 1.88 1.89 2.85 10.19

Profile*

Medicure Inc

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing MC-1 for the treatment of PNPO deficiency; and TARDOXAL for neurological indications, such as Tardive Dyskinesia. It offers products through retail and mail order pharmacies. The company was founded in 1997 and is headquartered in Winnipeg, Canada.

2-1250 Waverley Street, Winnipeg, MB, Canada, R3T 6C6

204 487 7412

https://www.medicure.com

Name Title Year Born
Dr. Albert David Friesen Ph.D. Founder, CEO & Chairman of the board 1947
Dr. Neil Owens Ph.D. Pres & COO NA
Mr. Haaris Uddin B.Com., CPA Chief Financial Officer NA
Dr. Reuben Saba Ph.D. VP of Scientific & Medical Affairs NA
Ms. Jamie Gowryluk VP of Commercial Operations NA
Dr. Neil Owens Ph.D. President & COO NA
Dr. Reuben Saba Ph.D. Vice President of Scientific & Medical Affairs NA
Dr. Albert David Friesen Ph.D. Founder, CEO & Chairman of the Board 1947

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…